This inventor holds 1 USPTO granted patent. Top assignees: Aurigene Discovery Technologies Limited, Um Pharmauji Sdn. Bhd.. Active years: 2015.
Company Filing History:

Years Active: 2015
Title: Muni Kumar Mahadari: Innovator in Anti-Bacterial Agents
Introduction
Muni Kumar Mahadari is a notable inventor based in Gadwal, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-bacterial agents. His innovative work has led to the creation of a patent that holds promise for therapeutic applications.
Latest Patents
Muni Kumar Mahadari holds a patent for "Substituted pyridine derivatives as FabI inhibitors." This invention provides substituted pyridine derivatives of formula (I), which may be therapeutically useful as anti-bacterial agents, specifically as FabI inhibitors. The patent details the formula (I) in which R1 to R5 and L have specific meanings as outlined in the specification. These compounds are beneficial in treating and preventing diseases or disorders where anti-bacterial agents are advantageous. The invention also includes methods for synthesizing and administering the FabI inhibitor compounds, as well as pharmaceutical formulations that comprise these compounds along with pharmaceutically acceptable carriers, diluents, or excipients.
Career Highlights
Throughout his career, Muni Kumar Mahadari has worked with various companies, including Aurigene Discovery Technologies Limited and Um Pharmauji Sdn. Bhd. His experience in these organizations has contributed to his expertise in pharmaceutical research and development.
Collaborations
Muni Kumar Mahadari has collaborated with notable colleagues such as Mohamed Takhi and Subramanya Hosahalli. These partnerships have likely enhanced his research efforts and innovation in the field.
Conclusion
Muni Kumar Mahadari is a distinguished inventor whose work in developing anti-bacterial agents has the potential to impact healthcare positively. His patent on substituted pyridine derivatives showcases his commitment to advancing pharmaceutical science.